COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #169
Source   Share   Tweet
See all 181 studies
Late treatment study
Self et al., JAMA, doi:10.1001/jama.2020.22240 (Peer Reviewed)
Effect of Hydroxych loroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial
Early terminated very late stage (65% on supplemental oxygen) RCT with 242 HC Q and 237 control patients not showing a significant difference, 28 day mortality adjusted odds ratio aOR 0.93 [0.48-1.85].
For the subgroup not on supplemental oxygen at baseline (relatively early treatment), the odds ratio for the 7 point outcome scale is:
aOR 0.61 [0.34-1.08]
Dosage may be too low:
Dose in first 24 hours - 1g (compare to Boulware et al. 2g)
Dose in 5 days - 2.4g (compare to Boulware et al. 3.8g)
Note the paper reports values with OR>1 favoring HC Q, we have converted to OR<1 favoring HC Q. Subgroup analysis is in the supplemental appendix.
death, ↓7.0%, p=0.84
Source   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.